Cell and Gene Therapy CDMO Targets North American Growth with Major US Acquisition

Date Published05/18/2023

Additional Reshoring Information:

Company/Division name uBriGene
Parent companyuBriGene
Type of work Manufacturing
Reshoring category:Foreign Direct Investment
Total number of jobs (added or to be added):500
Year reshoring announced:2023
Country(ies) from which reshored:Canada
City reshored to:Worcester
State(s) reshored to:MA
If relevant, work nearshored to:-
Product(s) reshoredmultiple gene-modified cell types, cGMP storage
What domestic positive factors made reshoring more attractive?Manufacturing/engineering joint innovation (R&D), Proximity to customers/market, Skilled workforce availability/training
Find Reshoring Articles